GBS....diagnostica futurista...ci proviamo
- Creatore Discussione mastrodaniel
- Data di inizio
Io dentro, ultra penalizzata dalle vendite di quelli là... Sperando sia un passaggio di consegne con altri grossi
andrealor
Nuovo Utente
- Registrato
- 25/5/15
- Messaggi
- 1.245
- Punti reazioni
- 30
Seneca71
Nuovo Utente
- Registrato
- 10/5/07
- Messaggi
- 12.512
- Punti reazioni
- 417
andamento inspiegabile....con l'aggiornamento dato ieri avrebbe dovuto volare e invece
pierlala
Nuovo Utente
- Registrato
- 15/6/17
- Messaggi
- 1.369
- Punti reazioni
- 47
andamento inspiegabile....con l'aggiornamento dato ieri avrebbe dovuto volare e invece
Oramai da un po' di tempo a questa parte, sulle small si ripete sempre la stessa storia...bastonate nel giorno degli ER con dati buoni...
E' come se MM abbia messo da parte la speculazione sulle small...
Che ci aspetta...?...
Seneca71
Nuovo Utente
- Registrato
- 10/5/07
- Messaggi
- 12.512
- Punti reazioni
- 417
Oramai da un po' di tempo a questa parte, sulle small si ripete sempre la stessa storia...bastonate nel giorno degli ER con dati buoni...
E' come se MM abbia messo da parte la speculazione sulle small...
Che ci aspetta...?...
Ciao Pier, chiedo venia per il ritardo ma il fol lo frequento col contagocce ultimamente...su GBS sono positivo da qualche giorno per due motivi: la consociata LSBD ha fornito da poco la spiegazione per cui ha venduto dei pacchetti azionari di GBS, secondo: con la variante sudafricana sono saliti alla ribalta nuovamente i titoli legati al covid e GBS con i suoi test salivari non può che benficiarne.
nin pos pio
Nuovo Utente
- Registrato
- 1/12/09
- Messaggi
- 732
- Punti reazioni
- 41
Cosi' ne riescono a scaricare di piu'
Seneca71
Nuovo Utente
- Registrato
- 10/5/07
- Messaggi
- 12.512
- Punti reazioni
- 417
Questa news varrebbe almeno, e dico almeno, un 100%....poi il titolo farà quello che vuole ma la news è pesante dal mio punto di vista
GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study
30/11/2021 14:00 RSF
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getne...rs.com:20211130:nGNX2L2H0J&default-theme=true
NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- GBS Inc.
(GBS Inc. - Real-time, point-of-care testing at the tip of your tongue) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it will commence preparation for clinical trials of its rapid SARS-CoV-2 Antibody test following the recent successful completion of a clinical validation study.
As previously referenced, a clinical validation study was conducted at the Wyss Institute for Biologically Inspired Engineering at Harvard University.
The objective of this study was to develop a diagnostic test to detect SARS-CoV-2 IgG in human plasma. The statistical design of the study was powered in accordance with this study objective. Preliminary findings were: * The SARS-CoV-2 Antibody biosensor assay was 100% sensitive and 100% specific using positive and negative SARS CoV-2 human plasma samples.
* The time in obtaining results was less than 10 minutes.
Following the above findings, the company is planning to commence clinical saliva SARS-CoV-2 Antibody trials, with the objective of submitting an Emergency Use Authorization (EUA) request to the United States Food and Drug Administration (FDA).
“We believe evidence from the validation study at the Wyss Institute supports the efficacy of our SARS-CoV-2 Antibody test, and we are now in a confident position to commence preparations for the next stage of trials,” Interim GBS CEO and Chairman of the Board, Dr. Steven Boyages said.
“Our objective is to deliver an antibody test to supplement the ongoing rollout of COVID-19 vaccines, and the subsequent testing of the global population. As we have witnessed with the Delta variant, and now the emerging Omicron variant, COVID-19 is going to be a part of our lives for the foreseeable future. It is therefore paramount we succeed in delivering our technology to the people that need it the most as soon as possible for both population and post-vaccination screenings.”
GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study
30/11/2021 14:00 RSF
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getne...rs.com:20211130:nGNX2L2H0J&default-theme=true
NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- GBS Inc.
(GBS Inc. - Real-time, point-of-care testing at the tip of your tongue) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it will commence preparation for clinical trials of its rapid SARS-CoV-2 Antibody test following the recent successful completion of a clinical validation study.
As previously referenced, a clinical validation study was conducted at the Wyss Institute for Biologically Inspired Engineering at Harvard University.
The objective of this study was to develop a diagnostic test to detect SARS-CoV-2 IgG in human plasma. The statistical design of the study was powered in accordance with this study objective. Preliminary findings were: * The SARS-CoV-2 Antibody biosensor assay was 100% sensitive and 100% specific using positive and negative SARS CoV-2 human plasma samples.
* The time in obtaining results was less than 10 minutes.
Following the above findings, the company is planning to commence clinical saliva SARS-CoV-2 Antibody trials, with the objective of submitting an Emergency Use Authorization (EUA) request to the United States Food and Drug Administration (FDA).
“We believe evidence from the validation study at the Wyss Institute supports the efficacy of our SARS-CoV-2 Antibody test, and we are now in a confident position to commence preparations for the next stage of trials,” Interim GBS CEO and Chairman of the Board, Dr. Steven Boyages said.
“Our objective is to deliver an antibody test to supplement the ongoing rollout of COVID-19 vaccines, and the subsequent testing of the global population. As we have witnessed with the Delta variant, and now the emerging Omicron variant, COVID-19 is going to be a part of our lives for the foreseeable future. It is therefore paramount we succeed in delivering our technology to the people that need it the most as soon as possible for both population and post-vaccination screenings.”
andrealor
Nuovo Utente
- Registrato
- 25/5/15
- Messaggi
- 1.245
- Punti reazioni
- 30
questa la news
GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody
i volumi in pre market ci sono
GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody
i volumi in pre market ci sono
M
Membro cancellato 234088
Guest
Grazie per la segnalazione, fatto un piccolo gain entrando in apertura. Avevo messo il take profit a 2,10$ ma poi mi cago sotto e vendo sempre prima del tempo e prima di quanto avevo fissato.
andrealor
Nuovo Utente
- Registrato
- 25/5/15
- Messaggi
- 1.245
- Punti reazioni
- 30
Ultima modifica:
il mio pt è uscire indenne... solo adesso mi sto accorgendo di quanto ero sotto
vediamo come evolve
andrealor
Nuovo Utente
- Registrato
- 25/5/15
- Messaggi
- 1.245
- Punti reazioni
- 30
arrivata a 2,70, rimani dentro?
venduto a 2,7
peccato regalare un 5% di capital gain per il cambio
andata di lusso... e adesso vado a prestare altri dollari ad erdogan